Related Experiment Video

Updated: Mar 13, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

715

Targeting acetaldehyde dehydrogenase 2 (ALDH2) in heart failure-Recent insights and perspectives

Jiaojiao Pang1, Jiali Wang1, Yingmei Zhang2

  • 1Department of Emergency, Qilu Hospital, Shandong University, Jinan, China; Chest Pain Center, Qilu Hospital, Shandong University, Jinan, China; Institute of Emergency and Critical Care Medicine, Shandong University, Jinan, China; Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Qilu Hospital, Shandong University, Jinan, China; Key Laboratory of Cardiovascular Remodeling & Function Research, Chinese Ministry of Education & Chinese Ministry of Public Health, Qilu Hospital, Shandong University, Jinan, China.

Biochimica Et Biophysica Acta. Molecular Basis of Disease
|October 16, 2016
PubMed

Insights

The ALDH2 rs671 gene variant influences heart failure risk by affecting conditions like hypertension and diabetes. Epigenetic factors further illuminate ALDH2's cardiovascular impact.

Area of Science:

  • Cardiovascular Science
  • Genetics
  • Molecular Biology

Background:

  • Heart failure is a leading global cause of mortality.
  • ALDH2 rs671 polymorphism is linked to heart failure risk factors such as hypertension, diabetes, and alcoholism.
  • Emerging evidence suggests ALDH2 plays a role in various heart failure types.

Purpose of the Study:

  • To review current understanding of ALDH2 polymorphism's effects on heart failure etiology.
  • To explore the underlying mechanisms of ALDH2's influence on heart failure.
  • To discuss the role of epigenetics in understanding ALDH2's cardiovascular effects.

Main Methods:

  • Mini-review of existing scientific literature.
  • Analysis of studies on ALDH2 rs671 polymorphism and cardiovascular disease.
  • Inclusion of recent findings on epigenetic modifications related to ALDH2.

Main Results:

  • ALDH2 rs671 is associated with key etiological factors of heart failure.
  • The review synthesizes evidence on ALDH2's direct and indirect roles in heart failure.
  • Epigenetic insights are highlighted as crucial for a comprehensive understanding.

Conclusions:

  • ALDH2 rs671 polymorphism significantly impacts heart failure prevalence through associated conditions.
  • Understanding ALDH2's mechanisms and epigenetic regulation is vital for cardiovascular health.
  • Further research into ALDH2 and epigenetics may offer novel therapeutic strategies for heart failure.

Keywords:
ALDH2Epigenetic regulationGenetic polymorphismHeart failure

More Related Videos

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

11.0K
A Modified Technique for Transverse Aortic Constriction in Mice04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

6.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
702
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.4K